The European Commission published today its proposal to create a European health data space (EHDS). The American Chamber of Commerce to the European Union (AmCham EU) supports this initiative that seeks to further bridge the digital gap in the life science and healthcare sectors. A common European approach for the use and re-use of health data has the potential to make the development of innovative health technologies at the scale of the EU easier and boost the creation of new treatments, therapies and medical devices.
European Health Data Space: an important tool to bridge the digital gap
The European Commission published today its proposal to create a European health data space (EHDS). The American Chamber of Commerce to the European Union (AmCham EU) supports this initiative that seeks to further bridge the digital gap in the life science and healthcare sectors. A common European approach for the use and re-use of health data has the potential to make the development of innovative health technologies at the scale of the EU easier and boost the creation of new treatments, therapies and medical devices.
In order to live up to the expectations of the EHDS, the co-legislators will need to ensure that the current lack of interoperability and standards is overcome and that a broad set of stakeholders – such as the life science and healthcare industry as well as third countries – will be included in the scope of the EHDS.
The EHDS, which is the first initiative of its kind, needs to carefully balance the needs for both legal certainty and adaptability required in the rapidly-changing domain of data science, in order to ensure that all stakeholders – patients, clinicians, payors, regulators and industry partners — can fully engage in and benefit from the EHDS. This will be best achieved through open, transparent and structured stakeholder involvement throughout the development and implementation of the EHDS. Furthermore, in order to foster trust in the EHDS, citizens need to be supported in exercising their rights and guided on the implications of new concepts such as data altruism.
The EHDS should ensure a consistent and efficient framework for the reuse of health data in order to support the development, access to and adoption of innovative solutions in Europe’s health systems, advancing health equity in the EU and globally. This framework must consider and promote international collaboration including third-country access to health data, noting that health threats know no borders, as exemplified by the COVID pandemic. AmCham EU is committed to the success of the EHDS as an opportunity to achieve better health for all citizens and address existing and future global health challenges.
Related items
Position Paper
11 Nov 2025
Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.
:focal())
News
27 Oct 2025
Advancing EU health policy through competitiveness and innovation
On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.
:focal())
News
9 Oct 2025
Advancing European healthcare in Strasbourg
From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.